BAM
ALXN

Belpointe Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Belpointe Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,935
Closed -$907K – 1269
2021
Q2 		$907K Buy
4,935
+683
+16% +$117K 0.07% 322
2021
Q1 		$650K Buy
4,252
+640
+18% +$99K 0.06% 343
2020
Q4 		$564K Sell
3,612
-223
-6% -$28.7K 0.05% 374
2020
Q3 		$439K Buy
3,835
+162
+4% +$17.5K 0.05% 356
2020
Q2 		$412K Buy
3,673
+361
+11% +$38.3K 0.05% 336
2020
Q1 		$297K Buy
+3,312
New +$325K 0.05% 342

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Belpointe Asset Management's ALXN Position: Q3 2021 in Review

Belpointe Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,935 shares — an estimated $907K sold.

Belpointe Asset Management first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $907K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Belpointe Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Belpointe Asset Management sold 4,935 Alexion Pharmaceuticals shares in Q3 2021, an estimated $907K.
  • Belpointe Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Belpointe Asset Management's Alexion Pharmaceuticals position peaked at $907K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Belpointe Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.